Acute stroke in patients on new direct oral anticoagulants: How to manage, how to treat?

Expert Opinion on Pharmacotherapy

Volumn 15, Issue 14, 2014, Pages 1991-2001

  Epple, Corina ^a   Steiner, Thorsten ^a,b  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Acute stroke; Apixaban; Dabigatran; Edoxaban; Novel oral anticoagulants; Oral factor Xa inhibitor; Oral thrombin inhibitor; Rivaroxaban; Stroke management; Warfarin

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; DABIGATRAN; RIVAROXABAN; THROMBIN INHIBITOR; BLOOD CLOTTING FACTOR; PROTHROMBIN COMPLEX CONCENTRATES; WARFARIN;

ANTICOAGULANT THERAPY; BLOOD CLOT LYSIS; BLOOD CLOTTING TEST; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; DISEASE ASSOCIATION; HUMAN; INTRAVENOUS THROMBOLYSIS; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; STROKE PATIENT; THROMBECTOMY; BLOOD; BLOOD CLOTTING; CEREBRAL HEMORRHAGE; CHEMICALLY INDUCED; DRUG EFFECTS; FIBRINOLYTIC THERAPY; ORAL DRUG ADMINISTRATION; STROKE;

ADMINISTRATION, ORAL; ANTICOAGULANTS; BLOOD COAGULATION; BLOOD COAGULATION FACTORS; BLOOD COAGULATION TESTS; CEREBRAL HEMORRHAGE; HUMANS; STROKE; THROMBOLYTIC THERAPY; WARFARIN;

EID: 84907051652     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2014.938638     Document Type: Review

References (83)

1. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361(12):1139-51.
2. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883-91
3. Granger CB, Alexander JH, Mc Murray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365(11):981-92
4. Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013;369(22):2093-104
5. Wittkowsky A. New oral anticoagulants: a practical guide for clinicians. J Thromb Thrombolysis 2010;29(2):182-91
6. Lindahl TL, Baghaei F, Blixter IF, et al. Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays. Thromb Haemost 2011;105(2):371-8
7. Fr eyburger G, Macouillard G, Labrouche S, Sztark F. Coagulation parameters in patients receiving dabigatran etexilate or rivaroxaban: two observational studies in patients undergoing total hip or total knee replacement. Thromb Res 2011;127:457-65
8. Samama MM, Guinet C. Laboratory assessment of new anticoagulants. Clin Chem Lab Med 2011;49(5):761-72
9. Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet 2008;47(5):285-95
10. van Ryn J, Stangier J, Haertter S, et al. Dabigatran etexilate-A novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010;103:1116-27
11. Mueck W, Eriksson BI, Bauer KA, et al. Population pharmacokinetics and pharmacodynamics of rivaroxaban-an oral, direct factor Xa inhibitor-in patients undergoing major orthopaedic surgery. Clin Pharmacokinet 2008;47(3):203-16
12. Wong PC, Crain EJ, Xin RR, et al. Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies. J Thromb Haemost 2008;6(5):820-9
13. Samama MM, Contant G, Spiro TE, et al. Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls. Thromb Haemost 2012;107(2):379-87
14. Harenberg J, Kraemer R. Measurement of the new anticoagulants. Thromb Res 2012;129(Suppl 1):S106-13
15. O'Donnell M,Oczkowski W,Fang J,et al, Preadmissi on antithrombotic treatment and stroke severity in patients with atrial fibrillation and acute ischaemic stroke: an observational study, Lancet Neurol, 2006, 5, 9, 749-54.
16. Rothwell PM, Coull AJ, Gile s MF, et al. Change in stroke incidence, mortality, case-fatality, severity, and risk factors in Oxfordshire, UK, from 1981 to 2004 (Oxford Vascular Study). Lancet 2004;363(9425):1925-33
17. Patel M R, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365(10):883-91
18. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Newly identified events in the RELY trial. N Engl J Med 2010;363(19):1875-6
19. Pfeilschifter W, Abruscato M, Hövelmann S, Baas H. Thrombolysis in a stroke patient on dabigatran anticoagulation: c ase report and synopsis of published cases. Case Rep Neurol 2013;5(1):56-61
20. Zalesak M, Siu K, Francis K, et al. Higher persistence in newly diagnosed nonvalvular atrial fibrillation patients treated w ith dabigatran versus warfarin. Circ Cardiovasc Qual Outcomes 2013;6(5):567-74
21. Rose AJ, Hylek EM, Ozonoff A, et al. Risk-adjusted percent time in therapeutic range as a quality indicator for outp atient oral anticoagulation: results of the Veterans Affairs Study to Improve Anticoagulation (VARIA). Circ Cardiovasc Qual Outcomes 2011;4(1):22-9
22. Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008;359(13):1317-29
23. Lees KR, Bluhmki E , von Kummer R, et al. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet 2010;375(9727):1695-703
24. Adams HP Jr, del Zoppo G, Alberts MJ, et al. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascul a r Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affirms the value of this guideline as an educational to ol for neurologists. Stroke 2007;38(5):1655-711
25. Levin D, Smith DB, Cumbler E, et al. Warfarin therapy does not increase risk of symptomatic intracerebral hemorrhage in eligible patients a fter intravenous thrombolysis. Arch Neurol 2011;68(1):135;author reply-6
26. Xian Y, Liang L, Smith EE, et al. Risks of intracranial hemorrhage among patients with acute ischemic stroke receiving war farin and treated with intravenous tissue plasminogen activator. JAMA 2012;307(24):2600-8
27. Diener H, Foerch C, Riess H, et al. Treatment of acute ischaemic stroke with thrombolysis or thrombectomy in p atients receiving anti-thrombotic treatment. Lancet Neurol 2013;12(7):677-88
28. Reilly PA, Lehr T, Haertter S, et al. The effect of dabigatran plasma concentrations and patient characteristics on th e frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). J Am Coll Cardiol 2014;63(4):321-8
29. Blombäck M , He S, Bark N, et al. Effects on fibrin network porosity of anticoagulants with different modes of action and reversal by activated coagulation factor concentrate. Br J Haematol 2011;152(6):758-65
30. Dempfle CE, Hennerici MG. Dabigatran and stroke thrombolysis. Cerebrovasc Dis 2010;30(2):203-5
31. Heidbuchel H, Verhamme P, Alings M, et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 2013;15(5):625-51
32. Hankey G, Norrving B, Hacke W, Steiner T. Recommendations for the emergency management of complications associated with new oral anticoagulants. Int J Stroke 2014;In print
33. De Smedt A, De Raedt S, Nieboer K, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator in a s troke patient treated with dabigatran. Cerebrovasc Dis 2010;30(5):533-4
34. Lee VH, Conners JJ, Prabhakaran S. Intravenous thrombolysis in a stroke patient taking dabigatran. J Stroke Cerebrovasc Dis 2012;21:916.e11-12
35. Matute MC, Guillan M, Garcia-Caldentey J, et al. Thrombolysis treatment for acute ischaemic stroke in a patient on treatment with dabigatran. Thromb Haemost 2011;106(1):178-9
36. Sangha N, El Khoury R, Misra V, Lopez G. Acute ischemic stroke treated with intravenous tissue plasminogen activator in a patient taking dabigatran with radiographic evidence of recanalization. J Stroke Cerebrovasc Dis 2012;21(8):917.e5-8
37. Casado Naranjo I,Portilla-Cuenca JC,Jim-enez Caballero PE,et al., Fatal intracerebral hemorrhage associated with administration of recombinant tissue plasminogen activator in a stroke patient on treatment with dabigatran, Cerebrovasc Dis, 2011, 32, 6, 614-15.
38. Pfeilschifter W, Bohmann F, Baumgarten P, et al. Thrombolysis with recombinant tissue plasminogen activator under dabigatran anticoagulation in experimental stroke. A nn Neurol 2012;71(5):624-33
39. Bohmann F, Mirceska A, Pfeilschifter J, et al. No influence of dabigatran anticoagulation on hemorrhagic transformation in an experimental model of ischemic stroke. PLoS On e 2012;7(7):e40804
40. Gliem M, Hermsen D, van Rooijen N, et al. Secondary intracerebral hemorrhage due to early initiation of oral anticoagulation after ischemic stroke: an experimental study in mice. St roke 2012;43(12):3352-7
41. Fluri F, Heinen F, Kleinschnitz C. Intravenous thrombolysis in a stroke patient receiving rivaroxaban. Cerebrovasc Dis Extra 2013;3(1):153-5
42. van Hooff R-J, Nieboer K, De Smedt A, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute ischemic stroke in a patient treated with rivaroxaban. Clin Neurol Neurosurg 2014. Available from : http://dx.doi.org/10.1016/j. clineuro.2013.12.029
43. Ploen R, Sun L, Zhou W, et al. Rivaroxaban does not increase hemorrhage after thrombolysis in experimental ischemic stroke. J Cereb Blood Flow Metab 2014;34(3):495-501
44. Broderick JP, Palesch YY, Demchuk AM, et al. Endovascular therapy after intravenous t-PA versus t-PA alone for stroke. N Engl J Med 2013;368(10):893-903 45.
45. Kidwell CS, Jahan R, Gornbein J, et al. A trial of imaging selection and endovascular treatment for ischemic stroke. N Engl J Med 2013;368(10):914-23
46. Ciccone A, V alvassori L, Nichelatti M, et al. Endovascular treatment for acute ischemic stroke. N Engl J Med 2013;368(10):904-13
47. Singh B, Parsaik AK, Prokop LJ, Mittal MK. Endovascular therapy for acute ischemic stroke: a systematic review and meta-analysis. Mayo Clin Proc 2013;88(10):1056-65
48. Sacco S, Marini C, Toni D, et al. Incidence and 10 year survival of intracerebral hemorrhage in a population-based registry. Stroke 2009;40:394-9
49. Flaherty ML, Kissela B, Woo D, et al. The increasing incidence of anticoagulant-associated intracerebral hemorrhage. Neurology 2007;68:116-21
50. Flibotte JJ, Hagan N, O'Donnell J, et al. Warfarin, hematoma expansion and outcome of intracerebral hemorrhage. Neurology 2004;63:1059-64
51. Hart RG, Boop BS, Anderson DC. Oral anticoagulants and intracranial hemorrhage. Facts and hypotheses. Stroke 1995;26:1471-7
52. Rosand J, Hylek EM, O'Donnell HC, Greenberg SM. Warfarin-associated hemorrhage and cerebral amyloid angiopathy: a genetic and pathologic study. Neurology 2000;55:947-51
53. Dowlatshahi D, Butcher KS, Asdaghi N, et al. Poor prognosis in warfarinassociated intracranial hemorrhage despite anticoagulation reversal. Stroke 2012;43(7):1812 -17
54. Aguilar MI, Hart RG, Kase CS, et al. Treatment of warfarin-associated intracerebral hemorrhage: literature review and expert opinion. Mayo Clin Proc 2007;82:82-92
55. Yasaka M, Sakata T, Minematsu K, Naritomi H. Correction of INR by prothrombin complex concentrate and vitamin K in patients with warfarin related hemorrhagic complication. Thromb Res 2002;108(1):25-30
56. Huttner HB, Schellinger PD, Hartmann M, et al. Hematoma groth and outcome in treated neurocritical care patients with intracerebral hemorrhage related to oral antikoagulant therapy. Comparison of acute treatment strategies using vitamin K, fresh frozen plasma, and prothrombin complex concentrates. Stroke 2006;37:1465-70
57. Steiner T, Freiberger A, Griebe M, et al. International normalised ratio normalisation in patients with coumarinrelated intracranial hae morrhages-the INCH trial: a randomised controlled multicentre trial to compare safety and preliminary efficacy of fresh frozen plasma and prothrombin complex-study design and protocol. Int J Stroke 2011;6(3):271-7
58. Steiner T,Bohm M,Dichgans M,et al, Recommendations for the emergency management of complications associated with new direct oral anticoagulants (doac) apixaban, dabigatran, and rivaroxaban, Clin Res Cardiol, 2013, 102, 399-412.
59. Wallentin L, Yusuf S, Ezekowitz MD, et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 2010;376:975-83
60. Zhou W, Schwarting S, Illanes S, et al. Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran. Stroke 2011;42:3594-9
61. Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011;364(9):806-17
62. Eerenberg ES, Kamphuisen PW, Sijpkens MK, et al. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulat ion 2011;124(14):1573-9
63. Leissinger CA, Blatt PM, Hoots WK, Ewenstein B. Role of prothrombin complex concentrates in reversing warfarin anticoagulation: a review of the literature. Am J Hemat ol 2008;83:137-43
64. Wagner F, Peters H, Formella S, et al. Effective elimination of dabigatran with haemodialysis: a phase I single-centre study in patients with end stage renal disease. American Heart Association Scientific S essions; 13-15 November 2011; Orlando, Florida
65. Siegal DM, Cuker A. Reversal of novel oral anticoagulants in patients with major bleeding. J Thromb Thrombolysis 2013;35(5):391-8
66. Ansell J. Blocking bleeding: reversing anticoagulant therapy. Nat Med 2013;19(4):402-4
67. Lu G, DeGuzman FR, Hollenbach SJ, et al. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med 2013;19(4):446-51
68. Schiele F, van Ryn J, Canada K, et al. A specific antidote for dabigatran: functional and structural characterization. Blood 2013;121(18):3554-62
69. Steiner T. Resumption of oral anticoagulants after warfarin associated intracerebralhaemorrhage: yes. Stroke 2011;42:3661-2
70. Ec kman MH, Rosand J, Knudsen KA, et al. Can patients be anticoagulated after intracerebral hemorrhage? A decision analysis. Stroke 2003;34:1710-11
71. Morgenstern LB, Hemphill JC III, Ander son C, et al. and the American Heart Association Stroke Council and Council on Cardiovascular Nursing. Guidelines for the management of spontaneus intracerebral hemorrhage: a guidline for healthcare professionals from the Amarican Heart Asso ciation/American Stroke Assiciation. Stroke 2010;41:2108-29
72. Apostolakis S, Lane DA, Guo Y, et al. Performance of the HEMORR 2 HAGES, ATRIA, and HAS-BLED bleeding risk-prediction scores in nonwarf arin anticoagulated atrial fibrillation patients. J Am Coll Cardiol 2013;61(3):386-7
73. Greenberg SM, Eng JA, Ning M, et al. Hemorrhage burden predicts recurrent intracerebral hemorrhage after lobar hemorrhage. Stroke 2004;35:1415-20
74. Eckman MH, Rosand J, Knudsen KA, et al. Can patients be anticoagulated after intracerebral hemorrhage? A decision analysis. Stroke 2003;34(7):1710-16
75. Molina CA, Selim MH. The dilemma of resuming anticoagulation after intracranial hemorrhage: little evidence facing big fears. Stroke 2011;42(12):3665-6
76. Pac iaroni M, Agnelli G. Should oral anticoagulants be restarted after warfarinassociated cerebral haemorrhage in patients with atrial fibrillation? Thromb Haemost 2014;111(1):14-18
77. Majeed A, Kim Y, Roberts R, et al. Optimal timimg of resumption of wafarin after intracranial hemorrhage. Stroke 2010;41:2860-6
78. Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and s afety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014;383(9921):955-62
79. Zhou W, Schwarting S, Illanes S, et al. Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran. Stroke 2011;42(12):3594-9
80. Zhou W,Zorn M,Nawroth P,et al. Hemostatic therapy in experimental intracerebral hemorrhage associated with rivaroxaban. Stroke 2013, 44, 3, 771-8.
81. Huisman MV, Lip GY, Diener HC, et al. Design and rationale of Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation: a global registry program on long-term oral antithrombotic treatment in patients with atrial fibrillation. Am Heart J 2014; 167(3):329-34
82. Veltkamp R, Jü ttler E, Pfefferkorn T, et al. Current registry studies of acute ischemic stroke. [Article in German]. Nervenarzt 2012;83(10):1270-4
83. Kakkar AK, Mueller I, Bassand JP, et al. International longitudinal registry of patients with atrial fibrillation at risk of stroke: global Anticoagulant Registry in the FIELD (GARFIELD). Am Heart J 2012;163(1): 13-19